Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Genitourinary 1

Conditions

Multiple Myeloma 1Immunoglobulin Light-chain Amyloidosis 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 1285Specimen Handling 928Carboplatin 837Magnetic Resonance Spectroscopy 834Cyclophosphamide 808Cisplatin 736Nivolumab 681Paclitaxel 635Radiotherapy 618Gemcitabine 580Biopsy 560Bevacizumab 486Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 363Fluorouracil 358atezolizumab 353durvalumab 340Rituximab 336Drug Therapy 334Radiosurgery 321Doxorubicin 320Blood Specimen Collection 317Standard of Care 311Pemetrexed 308Ipilimumab 303Radiation 289

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
MLN2238 × 1 year × Clear all
NCT03763162 2026-04-15

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
40 enrolled
Plasma cell

Multiple Myeloma

NCT03283917 2026-02-27

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
21 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03587662 2026-01-09

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡